	Association Between Efficacy and Pharmacokinetics of DMB-3115 and its Originator Ustekinumab in Patients with Chronic Plaque Psoriasis: An Exposure-Response Analysis. Adv Ther Konishi H, Shindo T, Ishiwata K, Morita J. PMID: 42599580 [PubMed - as supplied by publisher]
	Patient-centered approaches in psoriasis management: lessons from the past and future directions. Expert Opin Biol Ther McGuirt V, Breimann J, Gulati A, Huang W, Feldman S. PMID: 42598996 [PubMed - as supplied by publisher]
	Finerenone use and incident psoriasis in patients with type 2 diabetes and chronic kidney disease: A retrospective cohort study using the TriNetX network. JAAD Int Chuang WL, Chou RH, Wang YH, Tsai IJ, Lin CL, Cho DY, Chang KH. PMID: 42598181 [PubMed]
	Evaluating the psychosocial and clinical impact of diagnostic delay in psoriatic arthritis: insights from a monocentric cohort. Front Immunol Ferrigno S, De Vincenzo F, Panetta M, Arena M, Alessio C, Turri M, Vano L, Prevete I, Sensi F, Contardi A, Sebastiani GD. PMID: 42597693 [PubMed - indexed for MEDLINE]
	Dual zeitgeber axes in psoriasis: a chronobiological framework for immune jet lag. Front Immunol Lv H, Ling G, Mo H, Lu M, Yao D, Lu C. PMID: 42597665 [PubMed - indexed for MEDLINE]
	Disclosing the Overall and Sex-Related Disease Burden and Treatment Needs of Patients With Anogenital Psoriasis: Results From the Case-Control PsoGen Study. Dermatol Res Pract da Silva Burger N, Augustin M, Wilsmann-Theis D, Tsianakas A, Staubach-Renz P, Sommer R. PMID: 42597647 [PubMed]
	Adherence to Psoriasis Remote Monitoring and Its Associations With Demographic, Clinical, and Health Care Use Characteristics: Multicenter Observational Study. JMIR Form Res Lember M, Kruus P, Kaarna K, Traks T, Prett L, Raam L, Taul O, Ilves L, Viljar K, Konno P, Matasova S, Ross P, Kingo K. PMID: 42594362 [PubMed - indexed for MEDLINE]
	Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study. J Dermatolog Treat Muheyati D, Jiang Y, Xuan Z, Li S, Cui L, Ma R, Wang Y, Wang Y, Liu T, Zhang Y, Yu Q, Bi X, Shi Y. PMID: 42592795 [PubMed - indexed for MEDLINE]
	Correspondence on: "Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept AFFINITY Study". Arthritis Rheumatol Choudhuri B. PMID: 42592786 [PubMed - as supplied by publisher]
	Pilot validation of the genital psoriasis reported outcomes questionnaire in an Italian cohort. Front Med (Lausanne) Artosi F, Campione E, Lambiase S, Cattani C, Botti E, Zangrilli A, Bianchi L. PMID: 42591260 [PubMed]
	Association of IL-17 inhibitor therapy with glycemic, lipid profiles, and systemic inflammation in psoriasis patients with metabolic comorbidities: a retrospective cohort study. Front Med (Lausanne) Zhang X, Zhang M, Nie Z, Xu Y, Xu H, Li Y, Li J, Zhu M, Li J. PMID: 42591095 [PubMed]
	Potential Blood Biomarkers Predicting Treatment Response in Psoriasis: A Systematic Review and Meta-Analysis. J Clin Med Villa-Gonzalez JM, Arevalo-Ortega I, Gonzalez-Hermosa MR, Gonzalez S, Rashid S, Tsao H, Izu-Belloso R. PMID: 42590198 [PubMed]
	Inflammatory Manifestations, Therapeutic Interventions, and Cancer Risk in Psoriasis: Current Epidemiological and Mechanistic Evidence. Int J Mol Sci Lymperi A, Lamprianidou E, Adamantidi T, Chatzikamari M, Loizidis N, Dania V, Tsoupras A. PMID: 42589436 [PubMed - indexed for MEDLINE]
	Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety. J Dermatol Hagino T, Kanda N. PMID: 42587407 [PubMed - as supplied by publisher]
	Response to the letter by Ghanim et al, "Comment on Gao et al.'s 'A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis'". J Am Acad Dermatol Shi Y. PMID: 42586274 [PubMed - as supplied by publisher]
	Comment on Gao et al.'s "A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis". J Am Acad Dermatol Ghanim D, Ghebrial M, Tognaccini C, Thomas LE, Ansari Z, Gupta K, Wu JJ. PMID: 42586268 [PubMed - as supplied by publisher]
	Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis. Clin Drug Investig Rashid M, Muhammad A, Saeed E, Qureshi AA, Mubashir MM, Waqas Bin Waheed M, Yasin MA, Abdullah M, Rashid A, Zubair Z. PMID: 42584528 [PubMed - as supplied by publisher]
	Biologic DMARD class influences progression from psoriasis to PsA: A real-world cohort study. Rheumatology (Oxford) Kougkas N, Sotiriou E, Deligeorgakis D, Skepastianos V, Skouvaklidou E, Tsafis K, Vergou T, Michalakeas N, Papadimitriou I, Dimitroulas T, Fragoulis GE. PMID: 42584086 [PubMed - as supplied by publisher]
	Efficacy and safety of different doses of apremilast in mild to-moderate psoriasis: A randomized controlled study. Indian J Pharmacol Anil A, Saravanan A, Budania A, Yadav I, Dwivedi P, Varthya SB, Ambwani S, Singh S. PMID: 42583969 [PubMed - indexed for MEDLINE]
	Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review. J Dermatolog Treat Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. PMID: 42581417 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 28400

Page 1 of 1420



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy